CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma
James L. Rubenstein,Valerie S. Wong,Cigall Kadoch,Hua Xin Gao,Ramon F. Barajas,Lingjing Chen,S. Andrew Josephson,Brian J. Scott,Vanja C. Douglas,Mekhala Maiti,Lawrence D. Kaplan,Patrick A. Treseler,Soonmee Cha,Jimmy Hwang,Paola Cinque,Jason G. Cyster,Clifford A. Lowell +16 more
Reads0
Chats0
TLDR
It is demonstrated for the first time that elevated CXCL13 concentration in cerebrospinal fluid (CSF) is prognostic and that CXC chemokine ligand and IL-10 mediate chemotaxis of lymphoma cells isolated from CNS lymphoma lesions.About:
This article is published in Blood.The article was published on 2013-06-06 and is currently open access. It has received 178 citations till now. The article focuses on the topics: Lymphoma & CXCL13.read more
Citations
More filters
Journal ArticleDOI
The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis
Li Wang,Lan Luo,Zhe Gao,Shu-Feng Liu,Liu Chengjun,De-Xun Ma,Ji-Gang Chen,Wu-Rui Cao,Yin Aimin,Jia-Wen Xu,Wang Songlei,Du-Jun Zhuo,Bin Geng,Sha-Sha Zhao,Fei-Yan Wang,Nan Yang,Li-Xun Guan,Zhen-Yang Gu,Chun-Ji Gao +18 more
TL;DR: It was showed that CSF IL-10 is an effective diagnostic and prognostic biomarker for CNSL and was found to be associated with shorter progression-free survival.
Journal ArticleDOI
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Isabel Jiménez,Júlia Carabia,Sabela Bobillo,Carles Palacio,Pau Abrisqueta,Carlota Pagès,Juan C. Nieto,Josep Castellví,Francisco Martínez-Ricarte,Lourdes Escoda,Cristóbal Perla,Dennis H Céspedes Torrez,Joan Boix,Noelia Purroy,Noelia Purroy,Lluis Puigdefàbregas,Joan Seoane,Joan Seoane,Francesc Bosch,Marta Crespo +19 more
TL;DR: Pre-clinical evidence is provided for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential for primary central nervous system lymphoma.
Journal ArticleDOI
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma.
Patrizia Mondello,Patrizia Mondello,Salvatore Cuzzocrea,Carmela Arrigo,Vincenzo Pitini,Michael Mian,Francesco Bertoni +6 more
TL;DR: It is shown that tumor expression of activated STAT6 correlates with cerebral spinal fluid levels of its activator interleukins, IL-4 and IL-10, suggesting their potential use as surrogate biomarkers of JAK/STAT activation in patients with PCNSL.
Journal ArticleDOI
The potential for CXCL13 in CSF as a differential diagnostic tool in central nervous system infection.
TL;DR: Differences in study design, control groups and clinical parameters between studies, however, affect sensitivity, specificity and cutoff values, underlining the need of further studies to address these issues and pave the way for a generalized clinical practice.
Journal ArticleDOI
STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.
Xueliang Yang,Yaming Wang,Xuefei Sun,Xueyan Bai,Qu Cui,Hong Zhu,Jun Qian,Yuedan Chen,Shengjun Sun,Nan Ji,Yuanbo Liu +10 more
TL;DR: The results indicate that STAT3 activation is closely related to IL-10 expression and that p-STAT3 may be a novel biomarker predicting poor survival in PCNSL.
References
More filters
Journal ArticleDOI
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.
Mark H. Zweig,Gregory Campbell +1 more
TL;DR: Receiver-operating characteristic (ROC) plots provide a pure index of accuracy by demonstrating the limits of a test's ability to discriminate between alternative states of health over the complete spectrum of operating conditions.
Journal ArticleDOI
Basic principles of ROC analysis
TL;DR: ROC analysis is shown to be related in a direct and natural way to cost/benefit analysis of diagnostic decision making and the concepts of "average diagnostic cost" and "average net benefit" are developed and used to identify the optimal compromise among various kinds of diagnostic error.
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation
Yoji Hayashita,Hirotaka Osada,Yoshio Tatematsu,Hideki Yamada,Kiyoshi Yanagisawa,Shuta Tomida,Yasushi Yatabe,Katsunobu Kawahara,Yoshitaka Sekido,Takashi Takahashi +9 more
TL;DR: Findings clearly suggest that marked overexpression of the miR-17-92 cluster with occasional gene amplification may play a role in the development of lung cancers, especially in their most aggressive form, small-cell lung cancer, and that the C13orf25 gene may well be serving as a vehicle in this regard.
Journal ArticleDOI
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more
TL;DR: An international group of experts meeting to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow to develop better therapies for patients.
Related Papers (5)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Andrés J.M. Ferreri,Michele Reni,Marco Foppoli,Maurizio Martelli,Gerasimus A. Pangalis,Maurizio Frezzato,Maria Giuseppina Cabras,Alberto Fabbri,Gaetano Corazzelli,Fiorella Ilariucci,Giuseppe Rossi,Riccardo Soffietti,Caterina Stelitano,Daniele Vallisa,Francesco Zaja,Lucia Zoppegno,Gian Marco Aondio,Giuseppe Avvisati,Monica Balzarotti,Alba A. Brandes,José Luis Crespo Fajardo,Henry L. Gomez,Attilio Guarini,Graziella Pinotti,Luigi Rigacci,Catrina Uhlmann,Piero Picozzi,Paolo Vezzulli,Maurilio Ponzoni,Emanuele Zucca,Federico Caligaris-Cappio,Franco Cavalli +31 more
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more